SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback